Pfizer Corporation

Iteos Therapeutics

Agouron Pharmaceuticals, Inc.

Pfizer Products Inc.

Indrawan James McAlpine

Martin James Wythes

Eugene Yuanjin Rui

John Howard Tatlock

Sacha Ninkovic

Robert Arnold Kumpf

Ryan Patman

Andreas Maderna

Mehran Jalaie

Michele Ann McTigue

Susan Elizabeth Kephart

Michelle Bich Tran-Dube

Ketan Satish Gajiwala

Jingrong Jean Cui

Stefano Crosignani

Michael Raymond Collins

Scott Channing Sutton

Pei-Pei Kung

Andrew Fensome

Mary Catherine Johnson

Martin Paul Edwards

Luke Raymond Zehnder

Siegfried Heinz Reich

Lei Zhang

Robert Steven Kania

Cynthia Louise Palmer

Yufeng Hong

Haitao Li

Judith Gail Deal

Junhu Zhang

Chuangxing Guo

Stephanie Anne Scales

Joseph Scott Warmus

Jayashree Tikhe

Robert Ian Storer

Asako Nagata

Maria Angelica Linton

Mason Alan Pairish

Tuan Phong Tran

Sharanjeet Kaur Bagal

Sarah Elizabeth Skerratt

Liming Dong

Kiyoyuki Omoto

Anle Yang

Samantha Elizabeth Greasley

Elizabeth Ann Lunney

Dahui Zhou

Ethan Lawrence Fisher

Danlin Gu

Chan Woo Huh

Junhun Zhang

Jayashree Girish Tikhe

Modulators of STING (stimulator of interferon genes)

Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

Cyclopentane-based modulators of STING (stimulator of interferon genes)

Compounds of the general formula): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

Substituted carbonucleoside derivatives useful as anticancer agents

3-indol substituted derivatives, pharmaceutical compositions and methods for use

Compounds such as: processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds to treat neoplasms have been disclosed.

Substituted nucleoside derivatives useful as anticancer agents

This invention relates to compounds of general formula (I) in which R, R, U, V, L, M, R, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Aryl and heteroaryl fused lactams

The present invention relates to compounds of Formula I and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as TrkA antagonists.

Tropomyosin-related kinase inhibitors

Carbonylamino Pyrrolopyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4. 

Carbonylamino pyrrolopyrazoles, potent kinase inhibitors

The present invention is directed to compounds of Formula (I), and to pharmaceutically acceptable salts thereof, their synthesis, and their use as Raf inhibitors.

Pyrazole compounds as RAF inhibitors

3,5 disubstituted indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating CDK dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation

Growing community of inventors

San Diego, CA, United States of America

Indrawan James McAlpine